Increased cerebrospinal fluid cAMP levels in Alzheimer's disease

Brain Research

Volumn 846, Issue 2, 1999, Pages 265-267

  Martínez, Marcos ^a   Fernández, Estrella ^a   Frank, Ana ^a   Guaza, Carmen ^b   De La Fuente, Mónica ^c   Hernanz, Angel ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b INSTITUTO CAJAL   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Alzheimer's disease; cAMP; Cerebrospinal fluid; cGMP; Tau protein

Indexed keywords

CYCLIC AMP; CYCLIC GMP;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS;

AGED; ALZHEIMER DISEASE; CYCLIC AMP; CYCLIC GMP; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; SIGNAL TRANSDUCTION; TAU PROTEINS;

EID: 0344994681     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)01981-2     Document Type: Article

References (20)

1. Bancher C., Grundke-Iqbal I., Iqbal K., Fried V.A., Smith H.T., Wisniewski H.M. Abnormal phosphorylation of tau precedes ubiquitination in neurofibrillary pathology of Alzheimer disease. Brain Res. 539:1991;11-18.
2. Blass J.P., Gibson G.E. The role of oxidative abnormalities in the pathophysiology of Alzheimer's disease. Rev. Neurol. 148:1991;513-525.
3. Brandt R., Lee G., Teplow D.B., Shalloway D., Abdel-Ghany M. Differential effect of phosphorylation and substrate modulation on tau's ability to promote microtubule growth and nucleation. J. Biol. Chem. 269:1994;11776-11782.
4. Buxbaum J.D., Gandy S.E., Cicchetti P., Ehrlich M.E., Czernick A.J., Fracasso R.P., Ramabhadran T.V., Unterbeck A.J., Greengard P. Processing of Alzheimer beta/A4 amyloid precursor protein: modulation by agents that regulate protein phosphorylation. Proc. Natl. Acad. Sci. U.S.A. 87:1990;6003-6006.
5. Cashman R.E., Grammas P. cAMP-dependent protein kinase in cerebral microvessels in aging and Alzheimer's disease. Mol. Chem. Neuropathol. 26:1995;247-258.
6. Efthimiopoulos S., Punj S., Manolopoulos V., Pangalos M., Wang G.P., Refolo L.M., Robakis N.K. Intracellular cyclic AMP inhibits constitutive and phorbol ester-stimulated secretory cleavage of amyloid precursor protein. J. Neurochem. 67:1996;872-875.
7. Grammas P., Roher A.E., Ball M.J. Increased accumulation of cAMP in cerebral microvessels in Alzheimer's disease. Neurobiol. Aging. 15:1994;113-116.
8. Huang H.-M., Gibson G.E. Altered β-adrenergic receptor-stimulated cAMP formation in cultured skin fibroblasts from Alzheimer donors. J. Biol. Chem. 268:1993;14616-14621.
9. K. Horsburgh, T. Daitoh, Altered signal transduction in Alzheimer's disease, in: R.D. Terry, R. Katzman, K.L. Bick (Eds.), Alzheimer Disease, Raven Press, New York, 1994, pp. 387-404.
10. Lee R.K.K., Araki W., Wurtman R.J. Stimulation of amyloid precursor protein synthesis by adrenergic receptors coupled to cAMP formation. Proc. Natl. Acad. Sci. U.S.A. 94:1997;5422-5426.
11. Lee V.M.-Y., Balin B.J., Otvos L., Trojanowski J.Q. A 68: a major subunit of paired helical filaments and derivatized forms of normal tau. Science. 251:1991;675-678.
12. Litersky J.M., Johnson G.V.W., Jakes R., Goedert M., Lee M., Seubert P. Tau protein is phosphorylated by cyclic AMP-dependent protein kinase and calcium/calmodulin-dependent protein kinase II within its microtubule-binding domains at Ser-262 and Ser-356. Biochem. J. 316:1996;655-660.
13. Litersky J.M., Jhonson G.V.W. Phosphorylation by cAMP-dependent protein kinase inhibits the degradation of tau by calpain. J. Biol. Chem. 267:1992;1563-1568.
14. Malow B.A., Baker A.C., Blass J.P. Cultured cells as a screen for novel treatments of Alzheimer's disease. Arch. Neurol. 46:1989;1201-1203.
15. Papasozomenos S.C., Su Y. Altered phosphorylation of tau protein in heat-shocked rats and patients with Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 88:1991;4543-4547.
16. Peskin E.R., Wingerson D., Murray S., Pascualy M., Dobie D.J., Le Corre P., Le Verge R., Veith R.C., Raskind M.A. Effects of Alzheimer's disease and normal aging on cerebrospinal fluid norepinephrine responses to yohimbine and clonidine. Arch. Gen. Psychiatry. 52:1995;774-782.
17. Reinikainen K.J., Soininen H., Riekkinen P.J. Neurotransmitter changes in Alzheimer's disease: implications to diagnostics and therapy. J. Neurosci. Res. 27:1990;576-586.
18. Scott C.W., Spreen R.C., Herman J.L., Chow F.P., Davison M.D., Young J., Caputo C.B. Phosphorylation of tau by cAMP-dependent protein kinase. J. Biol. Chem. 268:1993;1166-1173.
19. Sims N.R., Finegan J.M., Blass J.P. Altered metabolic properties of cultured skin fibroblasts in Alzheimer's disease. Ann. Neurol. 21:1987;451-457.
20. Tato R.E., Frank A., Hernanz A. Tau protein concentrations in cerebrospinal fluid of patients with dementia of Alzheimer's type. J. Neurol., Neurosurg. Psychiatry. 59:1995;280-283.